Anti-inflammatory treatments may provide additional therapeutic benefits for individuals with high Lp(a), suggest Professor Winfried Marz (pictured left) and colleagues in the light of results from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study evaluating the effects of Lp(a), hsCRP, and interleukin-6 (IL-6) levels on cardiovascular mortality.
